Comment on faster access for patients to cannabis-based medicinal products (CBMPs) following relaxation of import restrictions by the Department of Health and Social Care (DHSC) and the Home Office.

The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.

Press Release: 3rd March 2020

Sativa Group Plc

(“Sativa” or “the Company” or “the Group”)

Comment on faster access for patients to cannabis-based medicinal products (CBMPs) following relaxation of import restrictions by the Department of Health and Social Care (DHSC) and the Home Office

Yesterday the Department of Health and Social Care (DHSC) and the Home Office announced that patients will be able to get faster access to cannabis-based medicinal products (CBMPs) through the relaxation of import restrictions. Sativa welcomes this initiative as it endorses the Group’s view that the UK is fast-developing as a significant medicinal cannabis market in which it intends to extend its participation and maintain its position as the UK’s leading quoted CBD wellness and medicinal cannabis Group.

Sativa Chief Executive Henry Lees-Buckley said: “Yesterday’s announcement by Matt Hancock, the Secretary of State for Health and Social Care, goes some way towards levelling the playing field and making cannabis-based remedies more affordable and accessible to all.

“However, there is still a long way to go to bring the UK in parallel with other countries where the benefits of cannabis-based remedies have been accessible for many years and the UK’s own medicinal cannabis industry remains very much fettered.”

Sativa is fortunate in holding one of the few Home Office Controlled Drug licences that allows it to cultivate, produce and supply cannabis for research purposes. It allows the Group to fulfil its agreement with King’s College London to supply the College with material as it researches the impact of cannabinoids on inflammation and respiratory diseases. That runs in parallel with the Group’s highly successful Goodbody CBD Wellness retail business and PhytoVista Laboratory service.

 – Ends –

Media enquiries

Abchurch Communications
Julian Bosdet
+44 (0)207 4594 4070
+44 (0) 7771 663 886

julian.bosdet@abchurch-group.com
www.abchurch-group.com

For further information please contact:

Henry Lees-Buckley
Chief Executive Officer
Sativa Group Plc
+44 (0) 20 7971 1255
enquiries@sativagroup.co.uk
www.sativagroup.co.uk

Joseph Colliver
Chief Financial Officer
Sativa Group Plc
+44 (0) 20 7971 1255
enquiries@sativagroup.co.uk
www.sativagroup.co.uk

NEX Exchange Corporate Adviser

Corporate Finance
Stephen Keys / Max Gould
Cenkos Securities plc
+44 (0) 20 7397 8900

Equity Sales
Julian Morse
Cenkos Securities
+44 (0) 20 7397 8900

Share on facebook
Share on google
Share on twitter
Share on linkedin

Published on

Categories